openPR Logo
Press release

Extracorporal Modified Immune Therapy (EMIT)

03-17-2016 01:31 PM CET | Health & Medicine

Press release from: PBirkel

A tumor patient usually does not die from a benign tumor, but from a malignant tumor that maintains an uninhibited proliferation, which in turn interferes fatally with the vital functions of other organs.

Apart from surgical procedures at an early stage, conventional cancer therapy is based on the philosophy that cancer cells should be destroyed with various destructive methods such as chemotherapy, radiation therapy, TKI, monoclonal antibodies, etc. All immunological research approaches also aim to destroy tumor cells; metaphorically speaking either by increasing the number of police officers (NK, T-cells etc.) or by re-arming them with more powerful weapons. Even the latest efforts with PD-1, CTLA-4 or CAR-T for cancer treatments are nothing else but a kind of “chemotherapy” with biological instrumentation. Apart from some few cancer entities which may indeed thus be treated successfully, this approach has only a limited effect and is applied merely with life-prolonging or palliative intention, not to mention of their unpredictable and high toxicity (more informationen).

EMIT follows an alternative way of action: On the basis of immunological instruction, malignant tumor cells are transformed into benign tumor cells. In the course of aging processes, the tumor cells recede and die off gradually (see images). After treatment, a residual tumor may still persist, but it is merely a harmless lump of abnormal tissue. In contrast to conventional therapies, the immune cells generated by EMIT remain almost a lifetime in the body, and they henceforth survey over the growth of tumor cells in question till the end of life.

What is necessary for performing an EMIT therapy? All we need is a piece tumor of 1-2 cm³ size containing living tumor cells, as well as some blood sample of patient approximately every third week. Depending on growth and reaction, cultured cells must then be re-injected into the patient about once per week. The whole treatment requires approximately 3 months.

Dr. med Sadik Öz (SOEZMED):
- STUDY (1979 − 1985)
Human Medicine at the University of Regensburg ( Physikum ) or University Erlangen-Nuremberg
- MEDICAL EDUCATION (1988 − 1995)
in the Med . Klinik III Uni – Erlangen Med . Clinic IV , Klinikum Nürnberg and Med . Clinic V , Nuremberg Hospital
September 1981 – September 1985 − Doctoral thesis
September 1985 – August 1986 − Assistant Professor at the Department of Immunology and Rheumatology,
Med . Klinik III Uni – Erlangen
September 1986 – June 1987 − Researcher at the Sloan Kettering Cancer Center, New York, USA
July 1987 – January 1988 − MHH Hannover Pediatric Oncology
February 1988 – December 1991 − Med. Klinik III Uni-Erlangen Haematological malignancies
July 1991 – August 1995 − Med. Klinik V, Klinikum Nürnberg Haematological malignancies
September 1995 to date − Independent researcher

Dr. med. Sadık Öz, Feuerweg 21, 90443 Nürnberg, +49 911 92919620

Peter Birkel
Bogenstr. 5
91233 Neunkirchen
Tel. + 49 9123 14957

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Extracorporal Modified Immune Therapy (EMIT) here

News-ID: 326710 • Views: 617

More Releases from PBirkel

03-17-2016 | Health & Medicine
The new concept: EMIT - CANCER IS CURABLE
The new concept: EMIT - CANCER IS CURABLE In the course of approximately 30 years in cancer research (see curriculum vitae) I have been trying to work out a new strategy to overcome the problems mentioned above. Based on my observations I assume that the mode of therapy should comprise not only the destruction of the tumor cell, but should focus on its “conversion”, “re-education” into normal functioning body cells. I
03-15-2016 | Health & Medicine
An alternative cancer treatment: Extracorporal Modified Immune Therapy (EMIT)
EMIT is based on the special cultivation of somatic tumor cells and leucocytes of patients, it would be subject to such regulation, too. Due to such financial and administrative obstacles it is almost impossible to offer this promising treatment for public use.  If a physician acts against these regulations, this would be regarded as an indictable offence as mentioned above. Moreover, other problems emerge: Those who do not belong to academic
03-14-2016 | Health & Medicine
May renal cell carcinoma be cured by EMIT?
A 50 year-old male patient asked for help: A left-sided renal mass had been detected in an abdominal CT-scan performed due to a preceding gross hematuria. Abdominal CT-scan: Inhomogeneous tumor with a diameter of approximately 9.5 cm in the left kidney. Additionally, several enlarged aortic lymph nodes (about 8 mm in size) as well as a tumor in the left adrenal with a diameter of 10 mm. Pathological evaluation Macroscopy: Left kidney,

All 4 Releases

More Releases for Med

MARIETTA, GEORGIA- APRIL 29, 2019- CAS MED SPA is excited to announce its CoolSculpting service, as well as a money saving promotional code. Available on their website at, patients can save $200 off their treatment. Going on through SPRING 2019, CAS MED SPA offers their best deal ever, up to $1500 with the purchase of six or more treatments! CoolSculpting is a revolutionary way to eliminate body fat. Unlike liposuction
World Bilateral Cochlear Implants Market 2018 - Cochlear, MED-EL
Apex Market Reports, recently published a detailed market research study focused on the “Bilateral Cochlear Implants Market” across the World, regional and country level. The report provides 360° analysis of “Bilateral Cochlear Implants Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the World PP Pipe industry, and estimates the future trend of Bilateral
Global Neurostimulator Devices Market 2018 - Schiller, Abiomed, MED-EL, Avazzia
The statistical surveying information incorporated into the Neurostimulator Devices report is the aftereffect of significant essential and optional research exercises. The report fragments the global Neurostimulator Devices market based on makers, item compose, applications, and regions. In this report, each fragment is contemplated completely and measurements are introduced in detail. The report offers an exact outline of the global Neurostimulator Devices advertise covering key factors, for example, drivers and restrictions
Nano Med Tech Hires Stateside Sales Team
Nano Med Tech, a newly emerging leader in nano-technological cancer research and treatment, announced that its sales team for America is in place and that stateside medical marketing will commence, soon. With a Commercial Director and eight account managers in place, Nano Med Tech will now seek to make its technology available in medical institutions throughout the United States. The organization has received USFDA approval for several patented medical devices, which utilize advanced
Nano Med Tech Announces Launch of New Website
Nano Med Tech, which has rapidly expanded its operations in the wake of recent progress in the area of malignant cell targeting, is pleased to announce the launch of its new website. The organization, which is on the cutting edge of nano-technology research and application, has officially launched its redesigned and updated website. “While it took awhile to get a product we were ultimately happy with, we couldn’t be
Maine Med and Tufts Create Medical School Program
A “uniquely Maine” curriculum and reserved slots for Maine students Imagine a medical school program run as a partnership by Maine’s largest hospital and the prestigious Tufts University School of Medicine. Imagine a “campus” that stretches from Boston to Portland and beyond, to rural Maine. Imagine 20 seats in each class reserved for Maine students at subsidized tuition levels. That’s just the beginning of what a unique partnership between Maine Med